Brief: Surface Oncology’s SRF617 Receives Orphan Drug Designation From FDA For Treatment Of Pancreatic Cancer
30/03/2021 21:42
March 30 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY’S SRF617 RECEIVES ORPHAN DRUG DESIGNATION
FROM
FDA FOR TREATMENT OF PANCREATIC CANCER
Source text for Eikon: ID:nGNXFdMzF
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing